Actuate Therapeutics Nasdaq/NYSE Compliance Notice
Actuate Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. This notice follows a separate July 2026 warning regarding the company's failure to meet the minimum market value of listed securities requirement.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days